Head-To-Head Contrast: Tonix Pharmaceuticals (TNXP) & Innovus Pharmaceuticals (INNV)

Innovus Pharmaceuticals (OTCMKTS: INNV) and Tonix Pharmaceuticals (NASDAQ:TNXP) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, dividends, profitability, analyst recommendations, earnings and valuation.

Analyst Ratings

This is a summary of recent ratings for Innovus Pharmaceuticals and Tonix Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Innovus Pharmaceuticals 0 0 0 0 N/A
Tonix Pharmaceuticals 0 1 4 0 2.80

Tonix Pharmaceuticals has a consensus price target of $8.33, indicating a potential upside of 104.75%. Given Tonix Pharmaceuticals’ higher possible upside, analysts plainly believe Tonix Pharmaceuticals is more favorable than Innovus Pharmaceuticals.

Earnings & Valuation

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Innovus Pharmaceuticals $4.82 million 3.24 -$13.70 million ($0.07) -1.36
Tonix Pharmaceuticals N/A N/A -$38.84 million ($4.77) -0.85

Innovus Pharmaceuticals has higher revenue and earnings than Tonix Pharmaceuticals. Innovus Pharmaceuticals is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Innovus Pharmaceuticals and Tonix Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Innovus Pharmaceuticals -102.95% -330.39% -72.75%
Tonix Pharmaceuticals N/A -78.25% -73.14%

Volatility & Risk

Innovus Pharmaceuticals has a beta of 4.02, suggesting that its stock price is 302% more volatile than the S&P 500. Comparatively, Tonix Pharmaceuticals has a beta of 2.92, suggesting that its stock price is 192% more volatile than the S&P 500.

Institutional & Insider Ownership

17.5% of Tonix Pharmaceuticals shares are owned by institutional investors. 19.1% of Innovus Pharmaceuticals shares are owned by insiders. Comparatively, 4.0% of Tonix Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Innovus Pharmaceuticals beats Tonix Pharmaceuticals on 6 of the 11 factors compared between the two stocks.

About Innovus Pharmaceuticals

Innovus Pharmaceuticals, Inc. is a pharmaceutical company engaged in the commercialization, licensing, and development of non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. The Company markets approximately five products in the United States and six in a range of countries around the world through its commercial partners. It has commercial agreements in over 60 countries around the world through its commercial partners. Its marketed products include Zestra, EjectDelay, Sensum+, Zestra Glide, Vesele and Androferti. In addition, the Company has a pipeline of over three additional products, including FlutiCare Over-The-Counter (OTC) for Allergic Rhinitis; Urocis XR, an extended release of Vaccinium Marcocarpon (cranberry), and AndroVit, a supplement to support overall prostate and male sexual health, which is marketed in Europe.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden. Its lead product candidate includes TNX-102 SL, a cyclobenzaprine HCl sublingual tablet, which is in Phase III clinical stage for the treatment of PTSD; and Phase III clinical stage for the treatment of military-related PTSD. The company’s product candidates also include TNX-601, an oral formulation of tianeptine oxalate for PTSD and cognitive dysfunction associated with steroid use; TNX-801, a smallpox-preventing vaccine based on a live synthetic version of horsepox virus; TNX-301, a fixed-dose combination drug product for alcohol use disorders; and TNX-701 for radiation injuries. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in New York, New York.

What are top analysts saying about Innovus Pharmaceuticals Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Innovus Pharmaceuticals Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit